Sandu Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹64.35
- Today's High:
- ₹73
- Open Price:
- ₹64.35
- 52W Low:
- ₹49
- 52W High:
- ₹78.35
- Prev. Close:
- ₹66.3
- Volume:
- 77755
Company Statistics
- Market Cap.:
- ₹215.26 million
- Book Value:
- 41.289
- Revenue TTM:
- ₹476.92 million
- Operating Margin TTM:
- 1.57%
- Gross Profit TTM:
- ₹217.38 million
- Profit Margin:
- 0.94%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Sandu Pharmaceuticals Limited had its IPO on under the ticker symbol 524703.
The company operates in the Other sector and Other industry. Sandu Pharmaceuticals Limited has a staff strength of 310 employees.
Stock update
Shares of Sandu Pharmaceuticals Limited opened at ₹64.35 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹64.35 - ₹73, and closed at ₹69.18.
This is a +4.34% increase from the previous day's closing price.
A total volume of 77,755 shares were traded at the close of the day’s session.
In the last one week, shares of Sandu Pharmaceuticals Limited have increased by +20.31%.
Sandu Pharmaceuticals Limited's Key Ratios
Sandu Pharmaceuticals Limited has a market cap of ₹215.26 million, indicating a price to book ratio of 0.6733 and a price to sales ratio of 0.4209.
In the last 12-months Sandu Pharmaceuticals Limited’s revenue was ₹476.92 million with a gross profit of ₹217.38 million and an EBITDA of ₹10.64 million. The EBITDA ratio measures Sandu Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sandu Pharmaceuticals Limited’s operating margin was 1.57% while its return on assets stood at 0% with a return of equity of 0%.
In Q2, Sandu Pharmaceuticals Limited’s quarterly earnings growth was a negative -88.6% while revenue growth was a negative 5.5%.
Sandu Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 44.127
- PEG
Its diluted EPS in the last 12-months stands at ₹0.621 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sandu Pharmaceuticals Limited’s profitability.
Sandu Pharmaceuticals Limited stock is trading at a EV to sales ratio of 0.4065 and a EV to EBITDA ratio of 12.0998. Its price to sales ratio in the trailing 12-months stood at 0.4209.
Sandu Pharmaceuticals Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹541.66 million
- Total Liabilities
- ₹138.83 million
- Operating Cash Flow
- ₹5.37 million
- Capital Expenditure
- ₹10.69 million
- Dividend Payout Ratio
- 0%
Sandu Pharmaceuticals Limited ended 2024 with ₹541.66 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹541.66 million while shareholder equity stood at ₹392.41 million.
Sandu Pharmaceuticals Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹138.83 million in other current liabilities, 96610000.00 in common stock, ₹295.80 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹22.96 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
Sandu Pharmaceuticals Limited’s total current assets stands at ₹255.45 million while long-term investments were ₹0 and short-term investments were ₹200000.00. Its net receivables were ₹47.92 million compared to accounts payable of ₹0 and inventory worth ₹143.26 million.
In 2024, Sandu Pharmaceuticals Limited's operating cash flow was ₹5.37 million while its capital expenditure stood at ₹10.69 million.
Comparatively, Sandu Pharmaceuticals Limited paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹69.18
- 52-Week High
- ₹78.35
- 52-Week Low
- ₹49
- Analyst Target Price
- ₹
Sandu Pharmaceuticals Limited stock is currently trading at ₹69.18 per share. It touched a 52-week high of ₹78.35 and a 52-week low of ₹78.35. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹55.61 and 200-day moving average was ₹58.99 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 5026.5% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Sandu Pharmaceuticals Limited
Similar Industry Stocks (Other)
Most Active
Top Gainers
Top Losers
About
Sandu Pharmaceuticals Limited manufactures and markets ayurvedic medicines under the SANDU brand in India and internationally. The company offers medicines in the areas of cardiovascular, endocrine, digestive, genito-urinary, muscular-skeletal, nervous, male reproductive, and respiratory system. It also provides medicines for gynecological; nutrition; skin; and ear, nose, and throat disorders. The company was founded in 1899 and is based in Mumbai, India.